ALL CONTENT OUTSOURCED PHARMA

• A Case For Paying Allogeneic Cell Therapy Product Donors
• Protecting Intellectual Property In The Genomics Revolution
• April 2025 — CDMO Opportunities And Threats Report
• Incorporating AI Tools Into Downstream Process Optimization
• NewBiologix Licenses Xcell-Eng-HEK293 Cell Line To ReciBioPharm For Development And Manufacture Of Adeno-Associated Virus (AAV) Therapeutics
• Is Early Automation The Key To Scalable Cell Therapy Manufacturing?
• A Road Map For PAT Monitoring And Control
• Hard Lessons In Parenteral Automatic Visual Inspection
• White Paper: Characterization Of Spray Dried Biologics
• Whitepaper: In Vivo Testing Of Nasal Dosage Forms
• The EU Biotech Act Has Been Delayed — Here's What That Means
• Building A Legacy In Sterile Injectables Through Strong CMO Synergy
• From Preparation To Compliance: DSCSA Implementation Takes Big Steps In 2025
• Bioanalytical Method Development Of Lipids, Peptides, And Small Molecules By LC-MS/MS
• Advanced Methodology Of PLGA-Based Parenteral Formulations
• Investors Create A U.S. Biotech With GLP-1 Assets From China
• Addressing Human "Error" In Pharma Manufacturing
• GeneFab And RegCell Announce Strategic Partnership To Advance Autoimmune Cell Therapy Into U.S. Clinical Trials
• Bionova Scientific Licenses ATUM's Proprietary Transposon-Based Gene Delivery Technology To Accelerate & De-Risk Cell Line Development
• Redefining Heart Failure Treatment with Precision Autologous Cell Therapy with BioCardia's Peter Altman, Ph.D.
• Vetter Prioritizes Continuity And Action In Its Sustainability Efforts
• Proper Care And Handling Of Coupons Used For Swab And Rinse Recovery Studies For Total Organic Carbon Analysis
• EMA Issues Draft Guideline On Quality Aspects Of mRNA Vaccines
• Almac Discovery And Formosa Pharmaceuticals Announce Global Licensing Agreement For Development And Commercialisation Of ALM-401, A First-In-Class EGFRxROR1 Bispecific Antibody-Drug Conjugate
• Hovione And Firstgene Announce Strategic Collaboration To Advance Virus-Like Particle Platform For Liver Cancer
• Microbix's Clot-Buster Drug Project Advances
• Roquette Announces A New Organization Following The Acquisition Of IFF Pharma Solutions
• Aptar CSP Technologies Expands Service Offerings With Launch Of cGMP Early-Stage Clinical Manufacturing Site For Tablet And Capsule-Based Drug Products
• The Expanding Role Of CMC In Biotech Investor Decision-Making
• Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, And Potential Opportunities For Expansion Into Southeast Asia
• Comprehensive, Integrated BioServices
• The Secret To True GMP-ness In The Cell & Gene Therapy Sector
• AustinPX Site Tour
• 8 Ways To Drive Resilience In Oncology Drug Supply Chains
• Do We Really Understand Plasmid Quality's Effects On mRNA Production?
• Commercializing RNAi Therapies With Alnylam's Tolga Tanguler
• The Serious Business Of Working With CDMOs At Phase 2
• Roquette Completes The Acquisition Of IFF Pharma Solutions
• SK pharmteco Opens New CGMP Plasmid Suite In King Of Prussia, Strengthening Commitment To Cell And Gene Therapy Innovation
• Using Virtual Reality To Enhance Aseptic Contamination Control
• Part Of $1B Investment Strategy, PCI Pharma Services Completes Acquisition Of Ajinomoto Althea, Enhancing US Drug Product Manufacturing For Aseptic Filling Of Prefilled Syringes & Cartridges
• AI Vs. Humans In Novel Drug Target Identification
• NorthX Biologics Receives CIR Accreditation To Support R&D Collaboration With French Biotech And Pharmaceutical Companies
• Novartis To Acquire Regulus Therapeutics And Farabursen, An Investigational MicroRNA Inhibitor To Treat ADPKD, The Most Common Genetic Cause Of Renal Failure
• ADC Heterogeneity, Site-Specific Conjugation
• Linker And ADC Platform Manufacturing Technologies
• Challenges In ADC Process Development
• AI In ADC Target Identification
• ADCs & Speed To IND
• Cytiva And Asimov Collaborate On Next Generation Cell Line Design And Process Development
• RoosterBio Announces Collaboration With Thermo Fisher Scientific To Advance Cell & Exosome Therapy Manufacturing
• Protein Stress Testing
• Analytical Development Services
• Stability Services
• Analytical Techniques For Characterization, Release, And Stability Testing
• Lean Thinking For Pharma — Flow Without Facility Upheaval
• Economic Advantage Of Robotic Gloveless Pharmaceutical Isolators
• CDMO Uses Robotic Gloveless Isolator For Advanced Therapeutics
• White Raven's Accelerated Path To GMP Certification
• Service Solutions Designed To Help You Gain Speed To Clinic And Market
• Biomay Obtains FDA Approval For Manufacturing Of Cas9 Nuclease At Headquarters Site
• Merck To Acquire US Biopharma Company SpringWorks Therapeutics To Accelerate Sustainable Growth Of Healthcare Business
• Lynn Cinelli's Wake-Up Call: Pharma's Forecasting Makes CDMOs Sick
• Catalent Capacity Update April 2025: Fill/Finish
• Bora Pharmaceuticals Capacity Update April 2025: Fill/Finish
• Simtra Biopharma Solutions Capacity Update April 2025: Fill/Finish
• Mabion Capacity Update April 2025: Fill/Finish
• Resilience Capacity Update April 2025: Fill/Finish
• Curia Capacity Update April 2025: Fill/Finish
• IDT Biologika Capacity Update April 2025: Fill/Finish
• FUJIFILM Diosynth Biotechnologies Capacity Update April 2025: Fill/Finish
• Argonaut Capacity Update April 2025: Fill/Finish
• A Checklist For Mechanism-Based Potency Testing In Cell Therapy
• Orion And Criceto Announce A License Agreement For APORON, An Innovative Apomorphine Spray To Treat OFF Episodes In Parkinson's Disease
• FUJIFILM Diosynth Biotechnologies Capacity Update April 2025: Cell & Gene Therapy
• PCI Pharma Services To Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea
• PDG-FDA Town Hall Notes — DSCSA Readiness Is At Hand
• Big Pharma Insights For Building Biotech Startups With Uniquity Bio's Brian Lortie
• The Strategic Role Of Cost Modeling In Pharmaceutical Procurement
• Vinta Bio Capacity Update April 2025: Cell & Gene Therapy
• Kincell Bio Capacity Update April 2025: Cell & Gene Therapy
• Comprehensive Cell Solutions Capacity Update April 2025: Cell & Gene Therapy
• Miltenyi Biotec B.V. & Co. KG Capacity Update April 2025: Cell & Gene Therapy
• Andelyn Capacity Update April 2025: Cell & Gene Therapy
• SK pharmteco Capacity Update April 2025: Cell & Gene Therapy
• Advancing Cell & Gene Therapies To Patients
• Tyber, Intech & Resolve Finalize Merger To Form Global CDMO+ For Musculoskeletal Device Solutions
• Pentixapharm Signs Contract Manufacturing Agreement For Yttrium-90-Based PentixaTher With Eckert & Ziegler SE
• Evotec Announces Significant Progress In Strategic Protein Degradation Collaboration With Bristol Myers Squibb
• ITM And Alpha-9 Oncology Enter Into Supply Agreement For Therapeutic Medical Radioisotope Actinium-225
• ICH Revises Q1 Guideline, Advancing Stability Testing Standards
• Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs
• Tariffs Won't Stop Drug-Candidate Licensing From China Biotechs
• Process Analytical Technology In The ADC Bioconjugation Process
• Common Manufacturing Challenges For LBP Formulations
• Cambrex Capacity Update April 2025: Small Molecule
• Bend Bioscience Capacity Update April 2025: Small Molecule
• SK pharmteco Capacity Update April 2025: Small Molecule
• Ropack Pharma Solutions Capacity Update April 2025: Small Molecule
• What CDMOs Wish Biotechs Knew Before Submitting An RFP
• Silexion Therapeutics Announces Collaboration With Global Therapeutics Leader Catalent On Advanced siRNA Formulation Development & Clinical Manufacturing Activities
• Phlow Corp. Expands Analytical Capabilities And Embraces Artificial Intelligence-Driven System, Ushering In A New Era Of Modern Medicine Manufacturing In America
• Northway Biotech Capacity Update April 2025: Large Molecule Development
• Abzena Capacity Update April 2025: Large Molecule Development
• Curia Capacity Update April 2025: Large Molecule Development
• Cytovance Biologics Capacity Update April 2025: Large Molecule Development
• Novartis Capacity Update April 2025: Large Molecule Development
• Samsung Biologics Capacity Update April 2025: Large Molecule Development
• Boehringer Ingelheim Capacity Update April 2025: Large Molecule Development
• Catalent Capacity Update April 2025: Large Molecule Development
• FUJIFILM Diosynth Biotechnologies Capacity Update April 2025: Large Molecule Development
• 8 Actions To Redefine Sponsor–CDMO Relationships
• Eurofins BioPharma Product Testing Capacity Update April 2025: Analytical Services
• Cambrex Capacity Update April 2025: Analytical Services
• Pace Life Sciences Capacity Update April 2025: Analytical Services
• Aragen Capacity Update April 2025: Analytical Services
• SK pharmteco Capacity Update April 2025: Analytical Services
• CARBOGEN AMCIS Shanghai Site Awarded Drug Manufacturing License From Chinese NMPA
• Roche To Invest USD 50 Billion In Pharmaceuticals And Diagnostics In The United States Over The Next Five Years
• Is An Outsourced BD Model Gaining Traction At CDMOs?
• AGC Biologics Capacity Update April 2025: ADC
• Simtra Biopharma Solutions Capacity Update April 2025: ADC
• Abzena Capacity Update April 2025: ADC
• Aragen Bioscience, Inc. Capacity Update April 2025: ADC
• Streamline Your Cell Therapy Manufacturing
• We Must Rethink The Solvents We Use For Peptide Synthesis
• 5 Steps To Design A Microbiological Performance Qualification For Facilities
• Early-Phase Whole-Body PK
• What Is Causing Limited Bioavailability
• Applied DNA's LineaRx Subsidiary Stands Ready To Support The Reshoring Of Drug Development And Manufacturing With U.S.-Produced Synthetic DNA
• Navigating Tariffs: Implications And Strategies For Pharmaceuticals Manufacturers
• Why You Need A Raw Material Control Strategy
• The Implications Of China's Growing Biotech Industry With Allan Shaw
• Why Pharma Risk Assessments Should Include 'Working Together Alone'
• Enabling mRNA Therapeutic Development Through Enhanced IVT Capping Efficiency
• Recent Developments Identifying Interactive Factors Affecting Tablet Scuffing Seen In The Aqueous Film Coating Process
• Mastering Technology Transfers: Our Blueprint For Success
• Ritedose Adds Seventh Syntegon Packaging Line To Expand Single Vial Packaging Capabilities, Support Production Of New COPD Drug Ohtuvayre
• Capricorn Scientific And Florabio Join Forces To Revolutionize Cell Culture Media In Biotech And Vaccine Industry With Animal-Free, High-Yield Solutions
• Climbing The Blockchain Ladder To Optimize Clinical Supply Forecasting
• Challenges In ADC Production - Consolidating Operations Under One Roof
• Pioneers And Visionaries: Cell Line Development And AAV Gene Therapy
• Ramping Up GMP-Compliant CAR-NK Manufacturing At Scale With iPSCs
• How CAR-NKs Offer Powerful Therapeutic Flexibility
• Pharmaceutical Sovereignty: The Resilience We Cannot Outsource
• Control Strategies And Method Development For Nitrosamines In APIs And Drug Products
• Cyprumed Enters License And Option Agreement With MSD For The Development Of Oral Peptide Therapeutics
• Lonza Joins Centre For Continuous Manufacturing And Advanced Crystallisation To Enhance Service Offering
• ThioBridge™ Conjugates
• Boehringer Ingelheim And Cue Biopharma Partner To Develop Next-Generation Treatment For Autoimmune And Inflammatory Diseases